FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments. The U.S. Food and Drug Administration (FDA) ...

Preclinical work has shown KRAS inhibition can delay cancer onset and extend survival in mice with pancreatic intraepithelial neoplasia lesions.

The field of cancer immunology has seen significant advancements in recent years, particularly with the emergence of immunotherapy as a key pillar in the ...

Short-Term Surgical Mission in Sub-Saharan Country, Experience of a Breast-Dedicated Team: Reviewing the Past and Stepping Toward the Last Mission Rapidly expanding systemic treatment options, ...

Cancer treatment has improved a lot in recent years, especially with the development of targeted drugs. These drugs are designed to attack cancer cells more precisely than older treatments like ...

Sept 2 (Reuters) - Zymeworks (ZYME.O), opens new tab said on Tuesday it will stop developing its experimental cancer drug after results from an early-stage trial showed the treatment was unlikely to ...

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...

A pioneering study has revealed new insights into the role of gastric bacteria in stomach cancer development that could pave the way for a more effective treatment of pre-cancer according to a study ...